UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunotherapy of Prostate Cancer: Facts and Hopes

Clinical cancer research, 2017-11, Vol.23 (22), p.6764-6770

2017

Volltextzugriff (PDF)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

The lancet oncology, 2018-01, Vol.19 (1), p.51-64

2018

Volltextzugriff (PDF)

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

JNCI : Journal of the National Cancer Institute, 2017-04, Vol.109 (4)

2017

Volltextzugriff (PDF)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Journal for immunotherapy of cancer, 2020-02, Vol.8 (1), p.e000433

2020

Volltextzugriff (PDF)

Vaccines as an Integral Component of Cancer Immunotherapy

JAMA : the journal of the American Medical Association, 2018-12, Vol.320 (21), p.2195

2018

Volltextzugriff (PDF)

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

Cancer immunology research, 2015-10, Vol.3 (10), p.1148-1157

2015

Volltextzugriff (PDF)

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

The lancet oncology, 2012-05, Vol.13 (5), p.501-508

2012

Volltextzugriff (PDF)

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

Oncoimmunology, 2017-10, Vol.6 (10), p.e1349589-e1349589

2017

Volltextzugriff (PDF)

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

The lancet oncology, 2017-05, Vol.18 (5), p.599-610

2017

Volltextzugriff (PDF)

The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

Clinical cancer research, 2019-12, Vol.25 (23), p.6916-6924

2019

Volltextzugriff (PDF)

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Molecular oncology, 2022-06, Vol.16 (11), p.2117-2134

2022

Volltextzugriff (PDF)

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1099-1105

2010

Volltextzugriff (PDF)

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

The oncologist (Dayton, Ohio), 2020-04, Vol.25 (4), p.290-300

2020

Volltextzugriff (PDF)

Product review: avelumab, an anti-PD-L1 antibody

Human vaccines & immunotherapeutics, 2019-04, Vol.15 (4), p.891-908

2019

Volltextzugriff (PDF)

Applications of large language models in cancer care: current evidence and future perspectives

Frontiers in oncology, 2023-09, Vol.13, p.1268915-1268915

2023

Volltextzugriff (PDF)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Journal for immunotherapy of cancer, 2018-05, Vol.6 (1), p.35-35, Article 35

2018

Volltextzugriff (PDF)

Utility of Large Language Models for Health Care Professionals and Patients in Navigating Hematopoietic Stem Cell Transplantation: Comparison of the Performance of ChatGPT-3.5, ChatGPT-4, and Bard

Journal of medical Internet research, 2024-05, Vol.26 (5), p.e54758-e54758

2024

Volltextzugriff (PDF)

Radium-223 mechanism of action: implications for use in treatment combinations

Nature reviews. Urology, 2019-12, Vol.16 (12), p.745-756

2019

Volltextzugriff (PDF)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Journal for immunotherapy of cancer, 2019-09, Vol.7 (1), p.240-240, Article 240

2019

Volltextzugriff (PDF)

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

Expert review of vaccines, 2018-08, Vol.17 (8), p.697-705

2018

Volltextzugriff (PDF)

An update on androgen deprivation therapy for prostate cancer

Endocrine-related cancer, 2010-12, Vol.17 (4), p.R305-R315

2010

Volltextzugriff (PDF)

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.111-111, Article 111

2018

Volltextzugriff (PDF)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Journal for immunotherapy of cancer, 2018-12, Vol.6 (1), p.141-141, Article 141

2018

Volltextzugriff (PDF)

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Clinical cancer research, 2011-02, Vol.17 (4), p.907-917

2011

Volltextzugriff (PDF)

1 – 25 von 699

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(650)
Mit Volltextzugriff
(598)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(699)
Japanisch
(43)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(169)
Journal For Immunotherapy Of Cancer
(66)
Clinical Cancer Research
(36)
Cancer Research
(31)
The Oncologist
(27)
The oncologist
(17)
The Journal Of Urology
(16)
The Journal Of Nuclear Medicine
(14)
Clinical Genitourinary Cancer
(13)
Bju International
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Immunotherapy of Prostate Cancer: Facts and Hopes

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Vaccines as an Integral Component of Cancer Immunotherapy

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

Product review: avelumab, an anti-PD-L1 antibody

Applications of large language models in cancer care: current evidence and future perspectives

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Utility of Large Language Models for Health Care Professionals and Patients in Navigating Hematopoietic Stem Cell Transplantation: Comparison of the Performance of ChatGPT-3.5, ChatGPT-4, and Bard

Radium-223 mechanism of action: implications for use in treatment combinations

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy

An update on androgen deprivation therapy for prostate cancer

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

Suchergebnisse filtern